Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.58 |
| ▸ | MAOA | P21397 | 2/20 | 0.51 |
| ▸ | MAOB | P27338 | 2/20 | 0.51 |
| ▸ | HTR1D | P28221 | 3/20 | 0.48 |
| ▸ | NCF1 | P14598 | 1/20 | 0.47 |
| ▸ | HTR1B | P28222 | 2/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | AKT1 | P31749 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NSD2 | O96028 | 1/20 | 0.43 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.43 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5531637 | 0.90 | HRH3 (0.51) | HRH3HTR1DNCF1HTR1BHTR1A | |
| SCHEMBL8095794 | 0.90 | HRH3 (0.58) | HRH3MAOAMAOBHTR1DNCF1 | |
| SCHEMBL5532963 | 0.90 | NCF1 (0.58) | HRH3MAOAMAOBHTR1DNCF1 | |
| SCHEMBL5529815 | 0.88 | NCF1 (0.51) | MAOAMAOBHTR1DNCF1HTR1B | |
| SCHEMBL8095832 | 0.87 | HRH3 (0.50) | HRH3MAOAMAOBHTR1DAKT1 | |
| SCHEMBL5529129 | 0.87 | HTR1D (0.52) | HTR1DNCF1HTR1BHTR1ASMN1; SMN2 | |
| SCHEMBL13945424 | 0.86 | HTR1D (0.47) | HRH3HTR1DNCF1HTR1BHTR1A | |
| SCHEMBL5531659 | 0.86 | HTR1D (0.57) | MAOAMAOBHTR1DNCF1HTR1B | |
| SCHEMBL14437441 | 0.85 | NCF1 (0.51) | MAOAMAOBHTR1DNCF1HTR1B | |
| SCHEMBL13969375 | 0.84 | HTR1D (0.42) | HRH3HTR1DNCF1HTR1BHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197509-A1 | Compositions and methods for modulating gated ion channels | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-08-23 | — | — | US | disclosed |
| US-20070197509-A1 | Compositions and methods for modulating gated ion channels | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-08-23 | — | — | US | disclosed |
| US-20070197509-A1 | Compositions and methods for modulating gated ion channels | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197509-A1 | Compositions and methods for modulating gated ion channels | KCNN3, KCNN2, HCN3 | HRH3 1454/4885MAOA 1975/4885MAOB 2080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.